MS Speaks

Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on December 21, 2018, 07:52:42 pm

Title: Pretreating Ocrevus patients w/antihistamines and liquids lowers infusion reactions by 60%
Post by: agate on December 21, 2018, 07:52:42 pm

"Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports" from Multiple Sclerosis News Today (December 18, 2018):

https://multiplesclerosisnewstoday.com/2018/12/18/pretreating-ms-patients-with-new-protocol-lowers-infusion-reactions-to-ocrevus-study-reports/?utm_source=Multiple+Sclerosis&utm_campaign=975c5ea29d-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-975c5ea29d-71286581
Title: New premed protocol improves ocrelizumab treatment for MS
Post by: agate on January 03, 2019, 07:09:22 pm
More on this from MD Magazine, January 3, 2019--"New Premed Protocol Improves Ocrelizumab Treatment for MS":


https://www.mdmag.com/medical-news/new-premed-protocol-improves-ocrelizumab-treatment-multiple-sclerosis